Spero Therapeutics (SPRO) News Today $0.91 +0.08 (+9.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Spero Therapeutics Inc SPROJanuary 16 at 5:20 PM | morningstar.comSpero Therapeutics Discloses Financial Estimates and Leadership Changes Amid SEC InvestigationOn January 7, 2025, Spero Therapeutics, Inc. (NASDAQ: SPRO) released a significant update and disclosed estimated financial information as of December 31, 2January 13, 2025 | americanbankingnews.comSpero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership ChangesJanuary 10, 2025 | finanznachrichten.deSpero Therapeutics announces interim leadership changesJanuary 10, 2025 | markets.businessinsider.comSpero Therapeutics Makes Interim Changes To Management After Wells Notice From SECJanuary 10, 2025 | markets.businessinsider.comSpero Therapeutics names Esther Rajavelu as Interim President and CEOJanuary 10, 2025 | msn.comSpero Therapeutics Provides Business Update and Announces Interim Leadership ChangesJanuary 10, 2025 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200-Day Moving Average - What's Next?December 28, 2024 | marketbeat.comSpero Therapeutics (SPRO) was downgraded to a Hold Rating at Evercore ISIDecember 23, 2024 | markets.businessinsider.comSpero Therapeutics downgraded at Evercore on lack of capital allocation clarityDecember 20, 2024 | markets.businessinsider.comEvercore ISI Group Downgrades Spero Therapeutics (SPRO)December 20, 2024 | msn.comWhat 4 Analyst Ratings Have To Say About Spero TherapeuticsDecember 20, 2024 | benzinga.comEvercore ISI Downgrades Spero Therapeutics (NASDAQ:SPRO) to In-LineEvercore ISI downgraded Spero Therapeutics from an "outperform" rating to an "in-line" rating and set a $5.00 target price on the stock. in a research report on Friday.December 20, 2024 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Below 200-Day Moving Average - What's Next?December 13, 2024 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for SPRO EarningsSpero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Spero Therapeutics in a report released on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share ofDecember 4, 2024 | marketbeat.comBuy Rating Reiterated for Spero Therapeutics Amid Promising Trial Progress and Strategic PartnershipDecember 3, 2024 | markets.businessinsider.comTD Cowen Downgrades Spero Therapeutics (SPRO)November 19, 2024 | msn.comSpero Therapeutics downgraded to Hold from Buy at TD CowenNovember 18, 2024 | markets.businessinsider.comSpero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD CowenTD Cowen restated a "hold" rating on shares of Spero Therapeutics in a research note on Monday.November 18, 2024 | marketbeat.comTD Cowen downgrades Spero Therapeutics (SPRO) to a HoldNovember 18, 2024 | markets.businessinsider.comSpero Therapeutics: Strategic Shift and Earnings UpdateNovember 16, 2024 | markets.businessinsider.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business UpdateNovember 15, 2024 | finanznachrichten.deSpero Therapeutics' (SPRO) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Spero Therapeutics in a research note on Friday.November 15, 2024 | marketbeat.comSpero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business UpdateNovember 14, 2024 | globenewswire.comSpero Therapeutics (SPRO) Set to Announce Earnings on ThursdaySpero Therapeutics (NASDAQ:SPRO) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports.November 8, 2024 | marketbeat.comQ3 EPS Estimate for Spero Therapeutics Boosted by AnalystSpero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now forNovember 6, 2024 | marketbeat.comHC Wainwright Lowers Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00HC Wainwright cut their price objective on Spero Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Monday.November 4, 2024 | marketbeat.comSpero’s stock slides after antibiotic flops in Phase II trialNovember 1, 2024 | msn.comCambridge biotech pulls plug on lung disease drug, cuts 39% of workforceNovember 1, 2024 | bizjournals.comSpero suspends development of SPR720, to reduce workforce by 39%October 30, 2024 | markets.businessinsider.comSpero Therapeutics Restructures Focus on Key R&D ProjectsOctober 30, 2024 | markets.businessinsider.comSpero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development ProgramOctober 29, 2024 | marketwatch.comSpero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business UpdateOctober 29, 2024 | markets.businessinsider.comSpero to cut 39% of workforce on failed study, stock plunges 20%October 29, 2024 | seekingalpha.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?October 27, 2024 | finance.yahoo.comSpero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024October 16, 2024 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average - Here's WhySpero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average - Should You Sell?October 15, 2024 | marketbeat.comSpero Therapeutics reports promising Phase 1 trial results for NTM-PD drugOctober 4, 2024 | uk.investing.comSpero Therapeutics (NASDAQ:SPRO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comPromising Clinical Developments Underpin Buy Rating for Spero TherapeuticsOctober 3, 2024 | markets.businessinsider.comSpero Therapeutics Reports Phase 1 Results Show Significant Lung Uptake Of SPR719October 3, 2024 | markets.businessinsider.comSpero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and ChemotherapyOctober 2, 2024 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average of $1.46Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average of $1.46September 24, 2024 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average of $1.48Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.48September 12, 2024 | marketbeat.comSpero Therapeutics to Present at Upcoming September Investor ConferencesSeptember 5, 2024 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.49Spero Therapeutics (NASDAQ:SPRO) Share Price Crosses Below Two Hundred Day Moving Average of $1.49August 27, 2024 | marketbeat.comEarnings call: Spero Therapeutics Q2 2024 update highlights pipeline progressAugust 10, 2024 | ca.investing.comSpero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comHC Wainwright Weighs in on Spero Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SPRO)Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Spero Therapeutics in a research report issued to clients and investors on Tuesday, August 6th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn (August 8, 2024 | marketbeat.comIndia's Marico says majority of retail distributors resume ops in BangladeshAugust 8, 2024 | uk.finance.yahoo.com Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRO Media Mentions By Week SPRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRO News Sentiment▼0.430.57▲Average Medical News Sentiment SPRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRO Articles This Week▼22▲SPRO Articles Average Week Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MacroGenics News Organigram News Inhibrx News MediWound News Artiva Biotherapeutics News ProQR Therapeutics News Procaps Group News Zentalis Pharmaceuticals News TuHURA Biosciences News Inhibikase Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRO) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.